^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

Chr t(11;14)(q13;q32)

11d
CAPITAL: Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P2, N=30, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Jun 2024
Trial completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Truqap (capivasertib)
14d
Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (clinicaltrials.gov)
P1/2, N=30, Recruiting, Chinese PLA General Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV
1m
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL (clinicaltrials.gov)
P1/2, N=33, Recruiting, Han weidong | Trial primary completion date: Dec 2023 --> Dec 2024
Trial primary completion date • CAR T-Cell Therapy
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • decitabine • fludarabine IV
2ms
ALTAMIRA: Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=81, Active, not recruiting, Nordic Lymphoma Group | Recruiting --> Active, not recruiting
Enrollment closed
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Rituxan (rituximab) • Calquence (acalabrutinib)
2ms
ACE-LY-004: An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=124, Active, not recruiting, Acerta Pharma BV | Trial completion date: Dec 2025 --> Sep 2026
Trial completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Calquence (acalabrutinib)
2ms
V-MIND: Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=100, Recruiting, Academic and Community Cancer Research United | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
CD19 (CD19 Molecule) • CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • CD19 expression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • lenalidomide • Monjuvi (tafasitamab-cxix)
2ms
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=50, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
Trial completion date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • Calquence (acalabrutinib)
2ms
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=50, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
Trial completion date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • Calquence (acalabrutinib)
2ms
Enrollment open • Combination therapy
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib)
3ms
CAPITAL: Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P2, N=30, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Aug 2023
Trial completion date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Truqap (capivasertib)
4ms
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=12, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2023 --> Sep 2025
Trial completion date • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Calquence (acalabrutinib) • Ukoniq (umbralisib) • Briumvi (ublituximab-xiiy)
6ms
ZEBRA: Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=50, Not yet recruiting, University College, London | Trial completion date: Dec 2027 --> Oct 2028 | Initiation date: Nov 2023 --> Apr 2024 | Trial primary completion date: Nov 2027 --> Oct 2028
Trial completion date • Trial initiation date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Rituxan (rituximab) • Brukinsa (zanubrutinib)
6ms
TrAVeRse: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=100, Not yet recruiting, AstraZeneca | Trial completion date: May 2028 --> Feb 2029 | Trial primary completion date: May 2028 --> Feb 2029
Trial completion date • Trial primary completion date • Combination therapy
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib)
7ms
TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL (clinicaltrials.gov)
P1/2, N=30, Recruiting, Chinese PLA General Hospital | Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | N=18 --> 30
Enrollment open • Phase classification • Enrollment change • CAR T-Cell Therapy
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV • ATHENA CAR-T
7ms
Toward cytogenomics: Technical assessment of long-read Nanopore whole-genome sequencing for detecting large chromosomal alterations in mantle cell lymphoma. (PubMed, J Mol Diagn)
The combined strength of long and short-read sequencing is apparent, where the high-precision junctional mapping complements and split paired-end reads. The potential is emphasized by the flexible single-sample genomic data acquisition of ONT with the high resolution of allelic imbalances using Illumina short-read sequencing.
Journal
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • Chr t(11;14)(q13;q32)
7ms
A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=7, Terminated, AstraZeneca | N=50 --> 7 | Trial completion date: May 2025 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Oct 2024 --> Aug 2023; Due to safety reasons.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
AZD0466
7ms
New P1 trial • New P1/2 trial • CAR T-Cell Therapy
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV • ATHENA CAR-T
8ms
V-MIND: Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=100, Not yet recruiting, Academic and Community Cancer Research United | Initiation date: Jul 2023 --> Nov 2023
Trial initiation date • Combination therapy
|
CD19 (CD19 Molecule) • CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • CD19 expression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • lenalidomide • Monjuvi (tafasitamab-cxix)
8ms
CAPITAL: Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P2, N=30, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=272 --> 30 | Trial completion date: Dec 2024 --> Dec 2023 | Trial primary completion date: Dec 2024 --> Dec 2023
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Truqap (capivasertib)
8ms
New P2 trial • Combination therapy
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib)
9ms
Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=30, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Jun 2023 --> Jun 2025
Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
|
CD20 positive • Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Imbruvica (ibrutinib) • Calquence (acalabrutinib)
9ms
ZEBRA: Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=50, Not yet recruiting, University College, London | Trial completion date: Apr 2027 --> Dec 2027 | Initiation date: Mar 2023 --> Nov 2023 | Trial primary completion date: Mar 2027 --> Nov 2027
Trial completion date • Trial initiation date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Rituxan (rituximab) • Brukinsa (zanubrutinib)
9ms
TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL (clinicaltrials.gov)
P1/2, N=38, Recruiting, Chinese PLA General Hospital | Initiation date: Dec 2022 --> Jun 2023
Trial initiation date
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV • autologous TRAC locus-inserted CD19-STAR-T
9ms
NOTCH Signaling in Mantle Cell Lymphoma: Biological and Clinical Implications. (PubMed, Int J Mol Sci)
At the clinical level, mutated NOTCH genes are associated with aggressive features in MCL, such as the blastoid and pleomorphic variants, a shorter response to treatment, and inferior survival. In this article, we explore in detail the role of NOTCH signaling in MCL biology and the ongoing efforts toward targeted therapeutic interventions.
Review • Journal
|
TP53 (Tumor protein P53) • ATM (ATM serine/threonine kinase) • NOTCH1 (Notch 1) • CCND1 (Cyclin D1) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
|
TP53 mutation • ATM mutation • Chr t(11;14) • Chr t(11;14)(q13;q32) • NOTCH mutation
9ms
New P2 trial • Combination therapy
|
CD19 (CD19 Molecule) • CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • CD19 expression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • lenalidomide • Monjuvi (tafasitamab-cxix)
10ms
ACE-LY-308: A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (clinicaltrials.gov)
P3, N=635, Active, not recruiting, Acerta Pharma BV | Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> Oct 2025 | Trial primary completion date: Apr 2023 --> Oct 2025
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase)
11ms
CAPITAL: Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P2, N=272, Recruiting, AstraZeneca | Trial completion date: Nov 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Truqap (capivasertib)
1year
Investigation of 13q14.3 deletion by cytogenetic analysis and FISH technique and miRNA-15a and miRNA-16-1 by real time PCR in chronic lymphocytic leukemia. (PubMed, Afr Health Sci)
We suggest that cytogenetic and iFISH analyses are complementary and use of DSP30+IL-2 is effective .in CLL. Decreased expression of hsa-miR-16-1 is remarkable.
Journal
|
IL2 (Interleukin 2) • MIR16 (MicroRNA 16) • MIR15A (MicroRNA 15a) • MIR16-1 (MicroRNA 16-1)
|
Chr t(11;14) • Chr t(11;14)(q13;q32)
1year
Trial completion date • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase)
1year
Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study. (PubMed, Cancers (Basel))
Despite the low number of patients treated with an MO approach, this study highlights the strengths and weakness of a molecular-targeted approach for the treatment of multiple myeloma. Widespread biomolecular techniques and improvement of precision medicine treatment algorithms could improve selection for precision medicine in myeloma.
Journal • IO biomarker
|
FGFR3 (Fibroblast growth factor receptor 3)
|
BRAF V600E • BRAF V600 • Chr t(11;14) • Chr t(4;14) • FGFR3 fusion • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • Balversa (erdafitinib)
1year
Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Calquence (acalabrutinib)
1year
Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma. (PubMed, J Hum Genet)
Moreover, the ISM-FISH showed a positive concordance of 96.6% and negative concordance of 98.8% with standard DC-FISH examining 1000 interphase cells. In conclusion, the ISM-FISH is a rapid and reliable diagnostic tool for the simultaneous examination of three critically important IGH translocations, which may promote risk-adapted individualized therapy in MM.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • CCND1 (Cyclin D1) • SDC1 (Syndecan 1)
|
Chr t(11;14) • Chr t(4;14) • Chr t(14;16) • Chr t(11;14)(q13;q32) • IGH translocation • SDC1 positive
1year
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=12, Active, not recruiting, City of Hope Medical Center | Suspended --> Active, not recruiting | N=27 --> 12
Enrollment closed • Enrollment change • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Calquence (acalabrutinib) • Ukoniq (umbralisib) • Briumvi (ublituximab-xiiy)
1year
Trial primary completion date • Combination therapy • Metastases
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
AZD0466
1year
Immunohistochemical and Molecular Genetic Profile of Mantle Cell Lymphoma of the Lacrimal Gland: A Case Series of an Uncommon Tumour of the Lacrimal Gland (PubMed, Klin Monbl Augenheilkd)
LG-MCL show an immunohistochemical profile corresponding to the classical profile of MCL. Overexpression of molecules for target therapies was found in all cases (CD20 for rituximab, BCL2 for Bruton-kinase-inhibitors and CD19 for CAR-T cell therapy). The removal of the GL can potentially drive to severe complications, even if aimed to confirm diagnosis. Therefore, the choice between GL-biopsy and exstirpation should be carefully evaluated, especially in cases of suspected lymphoma.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II)
|
CD20 positive • Chr t(11;14) • CCND1 expression • Chr t(11;14)(q13;q32)
|
Rituxan (rituximab)
1year
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients (clinicaltrials.gov)
P2, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
Enrollment open
|
TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • NOTCH2 (Notch 2) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
|
TP53 mutation • Chr del(17p) • CD20 positive • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification
|
Venclexta (venetoclax) • Jaypirca (pirtobrutinib)
over1year
A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=50, Recruiting, AstraZeneca | Trial completion date: Nov 2024 --> May 2025 | Trial primary completion date: Nov 2024 --> May 2025
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
AZD0466
over1year
New P2 trial
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Rituxan (rituximab) • Brukinsa (zanubrutinib)
over1year
New P1/2 trial
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV • autologous TRAC locus-inserted CD19-STAR-T
over1year
Enrollment open
|
TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • FAT1 (FAT atypical cadherin 1) • POT1 (Protection of telomeres 1) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
|
CD20 positive • Chr t(11;14) • KMT2D mutation • BIRC3 mutation • CCND1 overexpression • SMARCA4 mutation • Chr t(11;14)(q13;q32) • MYC positive
|
Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • fludarabine IV • Tecartus (brexucabtagene autoleucel)
over1year
Genotyping and Minimal Residual Disease (MRD) Assessment in cfDNA By the Euroclonality-NGS DNA Capture (EC-NDC) Panel in Mantle Cell Lymphoma (MCL) (ASH 2022)
Clinical data are still needed to explore the potential prognostic impact of MRD assessment in plasma vs PBC. Updated MRD analysis at EoT and correlation with clinical data will be presented at the meeting.
Next-generation sequencing • IO biomarker • Minimal residual disease
|
TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D)
|
Chr t(11;14) • Chr t(11;14)(q13;q32)
over1year
CARAMEL: Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=26, Not yet recruiting, University College, London | Trial completion date: Aug 2023 --> May 2026 | Trial primary completion date: Aug 2023 --> May 2026
Trial completion date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Rituxan (rituximab) • Calquence (acalabrutinib)